Bukola Ajanaku
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Bukola Ajanaku has a total of 52 co-authors. Here are the top co-authors by number of shared publications:
Anandita Rajpurohit
Lieber Institute for Brain Development, Johns Hopkins Medical Campus
1 shared publication- Aram Hong
Icahn School of Medicine at Mount Sinai
1 shared publication Atharv Chandra
Lieber Institute for Brain Development, Johns Hopkins Medical Campus
1 shared publication- Biao Zeng
Icahn School of Medicine at Mount Sinai
1 shared publication - Chris Chatzinakos
Department of Psychiatry and Behavioral Sciences, SUNY Downstate Health Sciences University
1 shared publication - Christian Dillard
Icahn School of Medicine at Mount Sinai
1 shared publication
Latest Publications
- Open Access
Single-nucleus transcriptome-wide association study of human brain disorders
Neuropsychiatric and neurodegenerative disorders exhibit cell-type-specific characteristics 1–8 , yet most transcriptome-wide association studies have been constrained by the use of homogenate brain tissue 9–11 , limiting their resolution and power. Here, we present a single-nucleus transcriptome-wide association study ( snTWAS ) leveraging single-nucleus RNA sequencing of over 6 million nuclei from the dorsolateral prefrontal cortex of 1,494 donors across three ancestries—European, African, and Admixed American. We constructed ancestry-specific single-nucleus-derived transcriptomic imputation models ( snTIMs ) including up to 27 non-overlapping cellular populations, enhancing the resolution of genetically regulated gene expression ( GReX ) in the brain and uncovering novel gene-trait associations across 12 neuropsychiatric and neurodegenerative traits. Our snTWAS framework revealed cell-type-specific dysregulation of GReX, identifying over 4,000 novel gene-trait associations not detected by bulk tissue approaches. By applying these snTIMs to the Million Veteran Program, we validated major findings and explored the pleiotropy of cell-type-specific GReX, revealing cross-ancestry concordance and fine-mapping causal genes. This approach enhances the discovery of biologically relevant pathways and gene targets, highlighting the importance of cell-type resolution and ancestry-specific models in understanding the genetic architecture of complex brain disorders.
Open AccessSingle-nucleus transcriptome-wide association study of human brain disorders
Neuropsychiatric and neurodegenerative disorders exhibit cell-type-specific characteristics 1–8 , yet most transcriptome-wide association studies have been constrained by the use of homogenate brain tissue 9–11 , limiting their resolution and power. Here, we present a single-nucleus transcriptome-wide association study ( snTWAS ) leveraging single-nucleus RNA sequencing of over 6 million nuclei from the dorsolateral prefrontal cortex of 1,494 donors across three ancestries—European, African, and Admixed American. We constructed ancestry-specific single-nucleus-derived transcriptomic imputation models ( snTIMs ) including up to 27 non-overlapping cellular populations, enhancing the resolution of genetically regulated gene expression ( GReX ) in the brain and uncovering novel gene-trait associations across 12 neuropsychiatric and neurodegenerative traits. Our snTWAS framework revealed cell-type-specific dysregulation of GReX, identifying over 4,000 novel gene-trait associations not detected by bulk tissue approaches. By applying these snTIMs to the Million Veteran Program, we validated major findings and explored the pleiotropy of cell-type-specific GReX, revealing cross-ancestry concordance and fine-mapping causal genes. This approach enhances the discovery of biologically relevant pathways and gene targets, highlighting the importance of cell-type resolution and ancestry-specific models in understanding the genetic architecture of complex brain disorders.
- Open Access
Transcriptomic analysis of the human habenula in schizophrenia
Pathophysiology of many neuropsychiatric disorders, including schizophrenia (SCZD), is linked to habenula (Hb) function. While pharmacotherapies and deep brain stimulation targeting the Hb are emerging as promising therapeutic treatments, little is known about the cell type-specific transcriptomic organization of the human Hb or how it is altered in SCZD. Here we define the molecular neuroanatomy of the human Hb and identify transcriptomic changes in individuals with SCZD compared to neurotypical controls. Utilizing Hb-enriched postmortem human brain tissue, we performed single nucleus RNA-sequencing (snRNA-seq; n=7 neurotypical donors) and identified 17 molecularly defined Hb cell types across 16,437 nuclei, including 3 medial and 7 lateral Hb populations, several of which were conserved between rodents and humans. Single molecule fluorescent in situ hybridization (smFISH; n=3 neurotypical donors) validated snRNA-seq Hb cell types and mapped their spatial locations. Bulk RNA-sequencing and cell type deconvolution in Hb-enriched tissue from 35 individuals with SCZD and 33 neurotypical controls yielded 45 SCZD-associated differentially expressed genes (DEGs, FDR < 0.05), with 32 (71%) unique to Hb-enriched tissue. eQTL analysis identified 717 independent SNP-gene pairs (FDR < 0.05), where either the SNP is a SCZD risk variant (16 pairs) or the gene is a SCZD DEG (7 pairs). eQTL and SCZD risk colocalization analysis identified 16 colocalized genes. These results identify topographically organized cell types with distinct molecular signatures in the human Hb and demonstrate unique genetic changes associated with SCZD, thereby providing novel molecular insights into the role of Hb in neuropsychiatric disorders. One Sentence Summary: Transcriptomic analysis of the human habenula and identification of molecular changes associated with schizophrenia risk and illness state.
Open AccessTranscriptomic analysis of the human habenula in schizophrenia
Pathophysiology of many neuropsychiatric disorders, including schizophrenia (SCZD), is linked to habenula (Hb) function. While pharmacotherapies and deep brain stimulation targeting the Hb are emerging as promising therapeutic treatments, little is known about the cell type-specific transcriptomic organization of the human Hb or how it is altered in SCZD. Here we define the molecular neuroanatomy of the human Hb and identify transcriptomic changes in individuals with SCZD compared to neurotypical controls. Utilizing Hb-enriched postmortem human brain tissue, we performed single nucleus RNA-sequencing (snRNA-seq; n=7 neurotypical donors) and identified 17 molecularly defined Hb cell types across 16,437 nuclei, including 3 medial and 7 lateral Hb populations, several of which were conserved between rodents and humans. Single molecule fluorescent in situ hybridization (smFISH; n=3 neurotypical donors) validated snRNA-seq Hb cell types and mapped their spatial locations. Bulk RNA-sequencing and cell type deconvolution in Hb-enriched tissue from 35 individuals with SCZD and 33 neurotypical controls yielded 45 SCZD-associated differentially expressed genes (DEGs, FDR < 0.05), with 32 (71%) unique to Hb-enriched tissue. eQTL analysis identified 717 independent SNP-gene pairs (FDR < 0.05), where either the SNP is a SCZD risk variant (16 pairs) or the gene is a SCZD DEG (7 pairs). eQTL and SCZD risk colocalization analysis identified 16 colocalized genes. These results identify topographically organized cell types with distinct molecular signatures in the human Hb and demonstrate unique genetic changes associated with SCZD, thereby providing novel molecular insights into the role of Hb in neuropsychiatric disorders. One Sentence Summary: Transcriptomic analysis of the human habenula and identification of molecular changes associated with schizophrenia risk and illness state.